AltruBio Secures $225 Million Series B

<p><strong>SAN FRANCISCO<&sol;strong> &&num;8212&semi; AltruBio Inc&period;&comma; a clinical stage biotechnology company dedicated to the development of novel therapeutics for the treatment of immunological diseases&comma; has raised an oversubscribed Series B financing of up to &dollar;225 million&period; AltruBio plans to use the proceeds of the financing to advance the clinical development of the Company’s first-in-class&comma; novel immune checkpoint enhancer &lpar;ICE&rpar; PSGL-1 agonist antibody&comma; ALTB-268&period; The funds will be used to support ongoing and planned Phase 2 clinical trials in ulcerative colitis &lpar;UC&rpar;&comma; one of many immunological disorders where the mechanism has been clinically validated&period;<&sol;p>&NewLine;<p>The financing was led by BVF Partners LP with participation from new investors RA Capital Management&comma; Cormorant Asset Management&comma; and Soleus Capital&comma; as well as existing investors aMoon Fund and Blackstone Multi-Asset Investing&comma; with other new and existing investors joining the syndicate&period;<&sol;p>&NewLine;<p>The Company’s first-in-class&comma; novel ICE agonist antibody&comma; ALTB-268&comma; is currently being studied in a Phase 2a exploratory biomarker study in patients with biologic refractory UC with an anticipated readout for its primary endpoint of clinical remission per modified Mayo score in 1H 2025&period; The company plans to initiate a global Phase 2b randomized&comma; placebo-controlled clinical trial with a primary endpoint of clinical remission in both advanced therapy experienced and treatment naive patients with moderately to severely active UC&period; This study is anticipated to read out in 2H of 2026&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We are honored to welcome this esteemed new group of investors&comma; whose participation complements the support of our existing world-class investor group&period; Their collective backing not only affirms the potential of our program and company but also our mission of developing durable biologic therapies for patients suffering from autoimmune diseases&comma;” said Dr&period; Judy Chou&comma; President and Chief Executive Officer of AltruBio&period; &OpenCurlyDoubleQuote;With this substantial investment&comma; we are one step closer to bringing our first-in-class&comma; novel immune checkpoint enhancer&comma; ALTB-268&comma; through our ongoing Phase 2a exploratory biomarker study and initiate an additional Phase 2b study&comma; while paving the way for potential indication expansion beyond ulcerative colitis&period; With our experienced team in place and this significant financing&comma; we are poised to accelerate our efforts and deliver innovative treatments to patients in need&period;&&num;8221&semi;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Treatment options remain limited in many autoimmune conditions&comma; including moderate to severe ulcerative colitis&comma; and novel mechanisms are sorely needed&comma;” commented Gorjan Hrustanovic&comma; Ph&period;D&period;&comma; Managing Director at BVF Partners LP&period; &OpenCurlyDoubleQuote;We are excited to support AltruBio and their commitment to developing a potential first-in-class medicine across multiple autoimmune indications&comma; starting with UC&period;”<&sol;p>&NewLine;